Nivestim (Filgrastim)

Filgrastim, the active ingredient in Nivestim, is a granulocyte colony‑stimulating factor presented as an injection for intravenous or subcutaneous use. It treats neutropenia associated with chemotherapy, bone marrow transplantation, and aplastic anemia. GNH USA supplies Nivestim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nivestim is a recombinant granulocyte colony‑stimulating factor used to manage conditions that cause low neutrophil counts. - Chemotherapy‑induced neutropenia: shortens the duration of severe neutropenia and reduces infection risk. - Neutropenia following bone marrow transplantation: accelerates neutrophil recovery after transplant procedures. - Aplastic anemia: stimulates production of neutrophils to mitigate neutropenia.

Nivestim may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Bone pain: aching discomfort often in the limbs or back. - Injection site reactions: redness, swelling, or tenderness at the injection site. - Fever: low‑grade temperature elevation. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and shock. - Acute respiratory distress syndrome: severe breathing difficulty. - Anaphylaxis: rapid onset of allergic reaction with hives, swelling, and airway compromise. - Capillary leak syndrome: hypotension and edema due to fluid shift. - Marked leukocytosis: excessively high white blood cell count. - Severe hypotension: sudden drop in blood pressure.

Before initiating Nivestim, clinicians should consider several safety factors. - Renal impairment: monitor renal function and adjust monitoring frequency. - Sickle cell disease: increased risk of vaso‑occlusive crisis; use with caution. - History of hypersensitivity: avoid if patient has known allergy to filgrastim or excipients. - Concurrent chemotherapy: closely observe blood counts to avoid overlapping myelosuppression. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other therapies, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with highly myelosuppressive chemotherapy agents: may blunt filgrastim efficacy. - Combination with other colony‑stimulating factors: risk of excessive leukocytosis. - Use with corticosteroids: potential reduction in filgrastim activity.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., quinolones): may affect neutrophil function. - Immunosuppressants such as cyclosporine: possible alteration of response. - Live attenuated vaccines: increased risk of infection; timing should be coordinated.